Viridian Therapeutics Confirms Veligrotug PDUFA Date, Reports Positive Elegrobart Phase 3 Data, and Strong Cash Position
VRDN is trading near its 52-week low of $11.76 (13% above the low).
Summary
Viridian Therapeutics confirmed a June 30, 2026 PDUFA date for veligrotug, announced positive Phase 3 data for elegrobart in TED, and reported a strong cash position of $762.2 million.
Key Events · Product Development and Regulatory · VRDN
-
Veligrotug PDUFA Date Confirmed
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026, for veligrotug in thyroid eye disease (TED). The company is launch-ready, having completed field team hiring and established commercial supply infrastructure.
-
Positive Elegrobart Phase 3 Data
Elegrobart (VRDN-003) showed positive topline data in both REVEAL-1 and REVEAL-2 Phase 3 clinical trials for active and chronic TED, respectively. Viridian plans to submit a Biologics License Application (BLA) in Q1 2027, aiming for the first subcutaneous autoinjector treatment for TED.
-
Strong Cash Position
The company reported cash, cash equivalents, and short-term investments of $762.2 million as of March 31, 2026, providing significant financial runway for ongoing operations and pipeline development.
-
Pipeline Advancement
Viridian is advancing its TSHR program with an IND submission anticipated in Q4 2026, and its FcRn inhibitor portfolio, with VRDN-006 development plans expected in 2026 and VRDN-008 Phase 1 healthy volunteer data on track for 2H 2026.
Analysis · VRDN · Life Sciences
This 8-K filing, accompanied by a press release, provides a comprehensive update on Viridian Therapeutics' pipeline and financial health. The confirmation of a June 30, 2026 PDUFA target action date for veligrotug, a Breakthrough Therapy Designated drug, signals a critical near-term catalyst for potential market entry. Furthermore, the positive topline data from both Phase 3 trials for elegrobart (REVEAL-1 and REVEAL-2) significantly de-risks the company's second major asset, positioning it as a potential first subcutaneous autoinjector treatment for Thyroid Eye Disease (TED) with a BLA submission anticipated in Q1 2027. While the company reported an increased net loss for Q1 2026, its robust cash position of $762.2 million provides substantial runway to advance its multiple clinical programs and support potential commercial launches.
At the time of this filing, VRDN was trading at $13.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $11.76 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.